SG3 Management’s Anika Therapeutics ANIK Stock Holding History

SG3 Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-75,000	Closed	-$2.65M	–	1005
2020 Q3	$2.65M	Buy	+75,000	New	+$2.71M	0.1%	225

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

SG3 Management's ANIK Position: Q1 2021 in Review

SG3 Management sold out of Anika Therapeutics (ANIK) in Q1 2021, closing a stake of 23,658 shares — an estimated $1.07M sold.

SG3 Management first reported a position in ANIK in Q4 2020 and held it in 1 quarter. The position peaked at $1.07M in Q4 2020. 146 funds tracked by Wall St. Rank hold ANIK as of Q1 2021.

SG3 Management reported no remaining Anika Therapeutics position as of Q1 2021 after selling out during the quarter.
SG3 Management sold 23,658 Anika Therapeutics shares in Q1 2021, an estimated $1.07M.
SG3 Management first reported a position in Anika Therapeutics in Q4 2020 and held it in 1 quarter.
SG3 Management's Anika Therapeutics position peaked at $1.07M in Q4 2020.
146 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2021.

Based on SG3 Management's 13F filing for Q1 2021, filed 17 May 2021.